US › Healthcare

Ensysce Biosciences Inc (ENSC)

US · Healthcare · Biotechnology

$0.33-8.95%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$1.2M

Revenue YoY

-15.1%

Net profit

$-2.6M

EPS

$-0.20

EPS estimate

$-0.50

Net margin

-220.8%

EPS came in at -0.20 against a street estimate of -0.50 — a beat of 60.0%.

Key statistics

Market cap

$7.0M

Forward P/E

0.9

P/B

0.86

Book value

$-0.05

EPS (TTM)

$-2.47

52-week high

$2.17

52-week low

$0.23

50-day MA

$0.45

200-day MA

$0.42

Beta

1.09

Analyst view

Analysts rate Ensysce Biosciences Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.12.

Shareholding

Insiders

4.72%

Institutions

4.65%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	1.07%
Adage Capital Partners Gp LLC	0.77%
Virtu Financial LLC	0.49%
Perceptive Advisors LLC	0.45%
Citadel Advisors Llc	0.44%
XTX Topco Ltd	0.40%
Geode Capital Management, LLC	0.32%
HRT FINANCIAL LLC	0.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ensysce Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.